Human Microbiome Market Outlook:
Human Microbiome Market size was over USD 0.6 billion in 2025 and is projected to register USD 8.2 billion by the end of 2035, expanding at a CAGR of 31.5% during the forecast timeline, i.e., 2026-2035. In 2026, the industry size of human microbiome is assessed at USD 0.7 billion.
The demand for prebiotics and probiotics driven by the rise in health awareness, is enhancing the growth of the global market. The engagement of consumers in various professional services leads to increased work pressure and long working hours, which can lead to a lack of a healthy diet, causing significant health issues and creating a lack of symbiotic microbiome. The growing adoption of prebiotics and probiotics with essential bacteria is expanding the growth of the human microbiome market.
Lowered intake of nutrients can often lead to poor functionality of the organs, and in exceptional cases, patients often experience organ failures with chronic diseases. Pharmaceutical manufacturers are advancing personalised medicines where the medications are tailored for patients with their microbiome requirements, ensuring progressive health and enhanced wellbeing. As patients often face side effects post consumption of profile-based medications, manufacturers’ stress on personalization eliminates the generic components and includes the essentials. The rising development of profile-based medication and diagnosis is expanding the human microbiome market. The demand for microbiome products is also propelled by the ageing population, where chronic diseases and health-related challenges are quite high. According to the World Health Organization, October 2025, nearly 1.4 million people globally will be over the age of 60, by 2050, which increases the risk of gut and immunity problems, prompting the use of microbiome supplements
Key Human Microbiome Market Insights Summary:
Regional Highlights:
- North America is anticipated to capture 47.5% share by 2035 in the human microbiome market, attributed to expanding pharmaceutical R&D initiatives and increasing approvals for advanced probiotic-based therapeutics.
- Asia Pacific is projected to secure a notable share by 2035, stimulated by growing preventive healthcare adoption and increasing investments in genomic sequencing and microbiome-based therapies.
Segment Insights:
- The probiotic segment is projected to account for a 42% share by 2035 in the human microbiome market, propelled by increasing consumer adoption of probiotics to enhance gut health and strengthen immunity.
- The oral segment is anticipated to secure a 55.2% share by 2035, impelled by rapid clinical trial approvals and growing preference for convenient, pain-free probiotic consumption methods.
Key Growth Trends:
- Prevalence of chronic diseases
- Growing innovation of pharmaceutical and research organizations
Major Challenges:
- Low clinician adoption
- Manufacturing constraint
Key Players: Vedanta Biosciences (U.S.), Seres Therapeutics (U.S.), Second Genome (U.S.), Rebiotix (Ferring Company) (U.S.), ActoGeniX (U.S.), Enterome Bioscience (France), 4D Pharma Research Ltd. (Japan), Yakult Honsha (Japan)
Global Human Microbiome Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 0.6 billion
- 2026 Market Size: USD 0.7 billion
- Projected Market Size: USD 8.2 billion by 2035
- Growth Forecasts: 31.5% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: North America (47.5% Share by 2035)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, Germany, China, Japan, United Kingdom
- Emerging Countries: South Korea, India, Singapore, Australia, Canada
Last updated on : 5 March, 2026
Human Microbiome Market - Growth Drivers and Challenges
Growth Driver
- Prevalence of chronic diseases: Increasing diseases among people, especially the aged individuals, are supporting in the growth of the human microbiome market. Lower nutrient intake or high consumption of foods with pathogenic microbiome can lead to the development of chronic diseases relating to the kidney, lungs and liver. The rise of chronic diseases has propelled the usage of prebiotics and probiotics, which can help in developing the enzymes and bacteria needed for wellbeing and better health. According to the National Library of Medicine 2025, the global cardiovascular diseases is expected to rise by more than 90% between the timeline 2025-2050, demonstrating the growing need for tailored medicines to organically supply essential microbiomes. Poor microbiome in the body and an unhealthy lifestyle can significantly increase bowel diseases, resulting in severe pain and discomfort. CDC in June 2024 stated that smoking and insomnia are the reasons behind inflammatory bowel disease, which turns chronic when not treated on time. IBD cases were estimated around 2.4 and 3.1 billion in the U.S. To overcome these chronic conditions, consumption of probiotics can significantly help in reducing such conditions, especially among smokers.
- Growing innovation of pharmaceutical and research organizations: The pharmaceutical companies are rapidly innovating their products and research on microbiome sequencing to enhance the benefits of therapy and medications. The support from the government and other public agencies is elevating the growth of the microbiome market. The Human Microbiome Project, undertaken by the National Institute of Health, aimed towards the understanding of human microbiome communities and delivering advanced and modern therapies, including tailored medicines, which can significantly help in reducing the risk of chronic health diseases, and improving the growth rate of various good microbiomes. The rising probiotic market and growing development of the microbiome market are propelling the expansion of the human microbiome market. In March 2024, BIOHM technologies partnered with Virginia Tech to integrate the Symbont platform with AI. The initiative was made to improve the identification and selection of ingredients that cover bacterial and fungal dysbiosis. BIOHM has the largest datasets that combine fungal and genetic sequencing of over 50 metadata points.
- Regulatory progress: The growing clinical trials of various microbiome product and their approval from agencies such as FDA and EMA are amplifying the market expansion. The success of these clinical trials is encouraging the pharmaceutical manufacturers to move towards commercialization. Profile-based diagnosis and therapies are also enhancing the market growth. In April 2023 FDA approved the first orally administered Faecal Microbiota product that can prevent Clostridioides difficile infection among individuals that are aged more than 18 years old. The development marked a significant step for the pharma companies to accelerate the expansion of the human microbiome market. Manufacturers across the globe are also emphasizing their research on developing diet-based supplements to administer among the older population who are at higher risk of suffering from microbiome gut infections caused by multiple pathogens.
Challenges
- Low clinician adoption: The adoption of microbiome products is lowered among clinicians because of trust issues with new diagnostic methods and therapies, which may bring an adverse impact on the patients. The growing stress of the pharmaceutical manufacturers in developing advanced therapies and diagnostic methods is leading to less intensive testing of the products, which can significantly reduce the adoption among clinicians, negatively impacting the growth of human microbiome market.
- Manufacturing constraint: Manufacturers face a strong challenge in terms of quality control and regulations which can significantly reduce the adoption of microbiome products. Manufacturers often exceed their operational costs to get their products certified to enhance the adoption of their products. For emerging pharma companies, certification costs could be a significant investment, which can potentially increase the cost of medicines and therapies, leading to reduced adoption in the market. The manufacturing constraint of high expenses and increased prices of final products is slowing the expansion of the human microbiome market.
Human Microbiome Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
31.5% |
|
Base Year Market Size (2025) |
USD 0.6 billion |
|
Forecast Year Market Size (2035) |
USD 8.2 billion |
|
Regional Scope |
|
Human Microbiome Market Segmentation:
Product Segment Analysis
The probiotic segment is expected to hold the largest share of 42% by the end of 2035, owing to the large-scale adoption among consumers to improve their gut health and immunity. Consumers, especially working professionals, are becoming aware of the lowered nutrient and macrobiotic intake that is propelling the expansion of the segment. Probiotic drinks and medicines are aimed towards the effective inclusion of good bacteria, which can improve immunity and enhance health. Probiotics are proven to support and improve the immune system of the human body and can be consumed by people of all age. The inclusion of probiotic among the younger children ensure sufficient growth of good bacteria enabling them to maintain strict health and reducing the risk of fatal diseases, enhancing the expansion of human microbiome market
Route Segment Analysis
The oral segment is expected to hold the largest share of 55.2% by the end of 2035 because of the rapid approval of clinical trials by various government agencies because of it effectiveness. The growth of probiotic drinks has been supported by the growth of the segment because of their lower complexity and easy consumption. The oral segment is pain-free and is highly recommended for ageing patients who are unable to take injections and IVs. Oral medications do not require complex formulations and barely takes time to consume making it highly adopted among consumers. Moreover, oral medicines can dissolve and affect faster further increasing dependency on the segment propelling the expansion of market.
Type Segment Analysis
The live bacteria segment is expected to hold a significant share by the end of 2035 because of rising concern among consumers regarding the availability of live good bacteria that improve gut health and immunity. The majority of the probiotic drinks are aimed towards the enhancement of good bacteria such as Lactobacillus and Saccharomyces boulardii, effective in reducing inflammation caused by chronic diseases and support immune system. The rise in microbiota therapies among the older population is also supportive of the segment growth, enhancing the scope of human microbiome market. As an ageing population reduces their food intake, the nutrient absorption lowers drastically, leading to a lack of good bacteria. Therapies and consumables integrated with probiotics and prebiotics are believed to have a significant impact on the ageing population and delivers the right number of bacteria within the human body.
Our in-depth analysis of the human microbiome market includes the following segments:
|
Segment |
Subsegments |
|
Product |
|
|
Disease |
|
|
Route |
|
|
CDMO |
|
|
Type |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Human Microbiome Market - Regional Analysis
North America Market Insight
The market in North America is expected to hold the largest share of 47.5% by the end of the forecast period, owing to the large-scale research and innovation among the pharmaceutical companies to develop advanced oral probiotic products that can deliver greater efficiency. The pharmaceutical companies gain momentum in the market because of recent approvals and clearance from healthcare bodies, propelling the expansion of the human microbiome market in North America. The growing academic collaborations between various universities in the region and healthcare facilities are advancing research in bioinformatics and metagenomics that is further amplifying the market expansion. Companies, such as Ferring Pharmaceutical collaborated with PharmaBiome, in December 2023 to enhance research and development to pioneer microbiome-based biotherapy that would cater to the gastroentology field. The rising consumer demand for improved gut health and immunity is further enhancing the expansion of the North America human microbiome market.
Canada consists of various research organisations that are directly impacting the growth of the market. Canadian pharmaceutical companies and research organisations are working closely to identify disease types and profile medicines accordingly to enhance the effectiveness. The growing initiative is effectively supporting the expansion of the human microbiome market in Canada. The rising consumer awareness is encouraging people to adopt preventive measures that can eliminate the risk of chronic diseases. The rising regulations and infrastructure development of the country have improved research organizations that are studying various cohorts of Gerontology, propelling advancements in probiotics and prebiotics, expanding the human microbiome market in Canada.
The strong regulations of U.S is encouraging the pharmaceutical manufacturers to advance genetic research and assess probable factors for poor microbiome availability. The growing stress of clinical trials is propelling interest among the pharmaceutical manufacturers to develop gene-based therapies and profile-based medications that can support the immune system. The U.S. has a large number of aged population that is at higher risk of gastrointestinal diseases. Probiotics for the aged population are extremely helpful, as the side effects are minimal while providing consistent health benefits. The rising consumer awareness, ageing population, and the growth of pharmaceutical manufacturers are effectively amplifying the growth of human microbiome market in the U.S. In September 2022, the American Gerontological Association shared data showing 40% of Americans stopped routine activities including exercise, resulting from bowel syndrome, demanding the use of microbiome products to improve gut health.
Asia Pacific Market Insight
The market in the Asia Pacific is expected to hold a significant share by the end of the forecast period because of rising preventive measures, where consumers from a young age are preferring microbiome products and therapies to ensure disease elimination. The population of the region is expanding rapidly, where the occurrence of chronic diseases is high, which reinforces the manufacturers to develop highly effective and efficient probiotic products to provide them the needed nutrients. The region is also growing in terms of new technologies and sequencing principles, which improve the efficacy of medicine and therapy to ensure supportive immunity among the population. The richness of countries in the region is enabling manufacturers to leverage AI and analytics to improve genomic sequencing and enhance the adoption of personalized medicines, and supporting the expansion of the APAC human microbiome market.
China is advanced in terms of technology, which is supporting the growth of the market. China’s technology firms and biomedical startups have partnered to provide patients with tailored interventions. The country holds a large population with dispersed income groups, where a certain group of people cannot afford microbiome-rich foods, leading to intense scarcity. The growing medicine subsidy and free healthcare assessments often promote the use of microbiome products, which can enhance immunity and strengthen it among patients and a certain selected group of people. China is experiencing a sudden rise in gastrointestinal disorders resulting in chronic conditions. Clinicians, as a result, are suggesting the adoption of prebiotic drinks, which can significantly improve the well-being of patients suffering from such chronic diseases, supporting the growth of the human microbiome market in China.
India’s healthcare infrastructure is rapidly developing, which is propelling the adoption of genome-based profiling and medications. The large-scale pharmaceutical companies and the growing research are advancing the adoption of the human microbiome market. In a recent technological development, India developed a swallowable pill that significantly collects samples from the intestine to assess the lacking enzymes, enhancing the growth of the market. The development of new research centres, such as the Centre of Excellence in Microbiome situated in Kerala, is directly supporting the growth of the human microbiome market. Advanced studies on functional food and prebiotic products are enhancing the growth of the market. In August 2025, Shilpa Medicare and Alveolus Bio collaborated to boost live therapeutic and small molecule platforms towards phase II of human clinical trials. The initiative will be support the growth of microbiome product advancements within the country, supporting the expansion of the business.
Key Human Microbiome Market Players:
- Vedanta Biosciences (U.S)
- Seres Therapeutics (U.S.)
- Second Genome (U.S.)
- Rebiotix (Ferring Company) (U.S.)
- ActoGeniX (U.S)
- Enterome Bioscience (France)
- 4D Pharma Research Ltd. (Japan)
- Yakult Honsha (Japan)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Seres Therapeutic is a biotechnology business that develops products to restore the functioning of the microbiome in the human body. The business focuses on the production of live drugs and targets serious diseases, restoring healthy bacteria. The business is also behind the production of the first oral microbial solution. With a global presence, the organization is delivering high-quality drugs that support immune systems and allow patients to recover faster.
- Second Genome is a U.S. based lifescience research organization that studies the human microbiome and its various therapies. The platforms enable the assessment of human physiology and microbiota types, which can help tailor medicines and therapies for the patients. The company has also combined machine learning and analytics for protein engineering and phage display that uncovers the biomarkers associated with human body.
- Rebiotix is a biotechnology company that focuses on microbiota-based therapies and was acquired by Ferring Pharmaceuticals. The business is also known for its own Microbiota Restoration that can seamlessly manage the healthy gut and enhance wellbeing. The business has a global footprint because of high-end therapies at affordable costs. It has specifically broadened deliver of the drugs by developing oral medicines.
- Enterome Bioscience is a leading clinical-stage, biopharmaceutical company that has strong research and innovation skills. The medicines and therapies innovated by the business are highly effective, enhancing their adoption in the global market. With a large global footprint, it is leading the oncology and immune-generated diseases. It has collaborated with large number of research institutes for biomarker discovery.
Here is a list of key players operating in the global market:
The competitors of the market are competing in terms of pricing and quality, which is leading to the development of cost-effective and high-quality probiotics. The market also experiences significant threats from well-established players because of advanced research and production equipment, which supports the growth of established businesses. Existing players keep developing their portfolios. The growing adoption of modern technologies among the key players is significantly supporting the growth of the human microbiome market.
Corporate Landscape of Human Microbiome Market
Recent Developments
- In November 2025, the International Union of Conservation announced the development of the Microbial Conservation Specialist Group to safeguard microbial life to achieve global biodiversity. The core priorities of the group is to assess, plan, network, communicate and initiate to minimize the growing threat of microbial life. The initiatives will also support key stakeholders to contribute to an international effort in saving critical microbial life.
- In October 2022, Seres Therapeutics announced the approval of a biologics license for an investigational microbiome therapeutic that can support the prevention of C.difficile infection. SER-109 is an investigational microbiome that is composed of purified firmicutes, helpful in the treatment of rCDI. The rising threat from the bacteria is a leading reason for death in the U.S.
- Report ID: 4062
- Published Date: Mar 05, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
Human Microbiome Market Report Scope
Free Sample includes current and historical market size, growth trends, regional charts & tables, company profiles, segment-wise forecasts, and more.
Connect with our Expert
Copyright @ 2026 Research Nester. All Rights Reserved.
